SUMMARY
INTRODUCTION
There has been a modest improvement in the five-year overall survival rate of epithelial ovarian cancer (EOC) from about 37% in 1975 to 45% in 2002 (1) . Factors contributing to this improvement include aggressive debulking and the introduction of platinum compounds and taxanes (2, 3) . Despite these improvements, most patients will relapse and develop refractory disease. Thus, the goal of second-line chemotherapy is palliation. Considerations in the choice of second-line therapy should include response to therapy and treatment related toxicity. Hormonal therapies are an attractive option owing to their limited toxicity profile and ease of administration (4) . we present a patient with advanced ovarian cancer who had stable disease on hormonal therapy for 28 months.
CASE
A 53-year-old woman presented with a two-week history of abdominal bloating. Pelvic examination revealed a 2-3 cm right adnexal mass. A CT scan confirmed the mass and showed abdominal and pelvic ascites. Serum CA-125 was elevated at 3050 U/ml (normal 0-35 U/ml). The patient underwent optimal debulking including total abdominal hysterectomy, bilateral salpingoophorectomy, omentectomy and lymph node sampling. Pathology demonstrated stage IIIC grade 2 papillary serous adenocarcinoma involving the omentum and peritoneal surfaces. Following surgery, the patient was treated with seven cycles of postoperative intravenous (IV) carboplatin and paclitaxel. CA-125 decreased but did not normalize (nadir = 66) in the setting of a negative physical exam. A peritoneal catheter was placed for purposes of intraperitoneal (IP) chemotherapy at which time persistent disease was documented histologically during the second-look surgery. She was given one cycle of IV cisplatin 65 mg/m 2 on day 1 and IV etoposide 90 mg/m 2 on days 1 through 3, while healing from the second-look surgery. Subsequently, she received five cycles of IP carboplatin 300 mg/m 2 on day 1 and IV etoposide 90 mg/m 2 on days 1 through 3 as second-line, took two months off from chemotherapy, and then received one cycle of IP carboplatin and two cycles of IP carboplatin and IV etoposide at the above doses. CA-125 increased from 27 to 54, so she received five cycles of single agent IV paclitaxel 185 mg/m 2 as third-line therapy. CA-125 decreased to 24 at the completion of paclitaxel. CT scans and pelvic exam always remained negative, and she had no symptoms of her disease. Because hormone receptors on her original tumor were determined to be positive for both estrogen and progesterone, she started with tamoxifen 20 mg per day. 
DISCUSSION
In platinum-resistant patients, there are a number of cytotoxic agents that have activity based on retrospective studies and phase II trials with objective response rates varying from 5 to 25%, and the duration of these responses lasting less than 8 months. An additional 35 to 50% of patients may maintain stable disease. The main advantage of using hormonal therapy among second-line therapy options is its limited toxicity profile and ease of administration, making it a suitable option for patients who are unable to tolerate or do not desire to continue cytotoxic chemotherapy due to side effects or comorbidities contraindicating the use of cytotoxic agents (4) . In this patient, despite rising CA-125 levels after ultimately developing resistance to tamoxifen, the subsequent use of anastrozole and fulvestrant still resulted in stable disease. Thus, resistance to one hormonal therapy does not preclude trial of another. One explanation is the differing mechanisms of actions of each of these agents. Tamoxifen and fulvestrant bind to estrogen receptors. Tamoxifen has some agonist activity whereas fulvestrant does not. Anastrozole is an aromatase inhibitor that blocks the peripheral conversion of androgens to estrogen, thereby decreasing the total amount of estrogen in the body. Tamoxifen is the most studied of the three agents. In a large prospective study, patients with recurrent or persistent disease (platinum-sensitive and resistant) given tamoxifen 20 mg per day after first-line chemotherapy, a 17% objective response was observed (5) . Analysis limited to platinumresistant patients showed an overall response rate (of 13%) (6). Tamoxifen does not appear to improve responses in combination with cytotoxic agents (7, 8) . Clinical studies using letrozole have shown conflicting results. One study showed an objective response of 15%; the other showed no objective responses (9, 10) . Fulvestrant 500 mg IM on day 1, 15, and 250 mg IM on day 28 and monthly thereafter has been studied in patients with recurrent EOC. Objective response rates were 8% with another 35% achieving stable disease (11) . Other options for hormonal therapy include gonadotropin analogs, progesterones, and androgens. A review of published papers on the use of tamoxifen alone or in combination with other agents, aromatase inhibitors, and fulvestrant in recurrent EOC is shown in Tables 1-5 . Of published studies that likely had overlapping patients, the study with a higher number of patients or analysis of the overall data (versus a subpopulation) were included.
Other factors thought to affect response to therapy include dosage and receptor status. Higher doses of tamoxifen in breast cancer have not been shown to be more effective and may even be more toxic (12) (13) (14) . Dose escalation in uterine cancer has shown similar results (15) . There are no data comparing dose responses of tamoxifen or other antiestrogen therapy in ovarian cancer. Varying doses (20 mg to 160 mg) and regimens of tamoxifen have been used. Estrogen and progesterone receptors are thought to play a role in the development of EOC and their presence would be expected to correlate with response to hormonal therapy in ovarian cancer as in breast cancer. However, the role that receptor status plays in the response to hormonal therapy in ovarian cancer remains unclear and should not necessarily influence treatment choices. A few trials suggest that response to tamoxifen may be related to hormone receptor status (5, 16, 17) , but no studies have been specifically designed to examine this effect. Our patient had one of the longest remissions reported to hormonal therapy. Hormonal therapy may have some activity in a subset of EOC patients with endocrine sensitivity. It should be considered in patients unable to tolerate cytotoxic chemotherapy or in the palliative setting as most of the literature focuses on patients with refractory or progressive disease. Further studies are needed to better characterize the role of hormonal therapy in ovarian cancer. CR: complete response; PR: partial response; SD: stable disease; PD: progressive isease; PFS: progression free survival; OS: overall survival; ER: estrogen receptor; NA: data not available in this study; f/b: followed by. 
